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FK 506 Has no Short-Term Effects on Endogenous or Exogenous 
Myeloid Reconstitution in Irradiated Mice 
S. Boggs, K. Patrene, F. Vecchini, P. Markus, M. Cooper, R. Duquesnoy, T.E. Starzl, and W. Bloomer 
I N this study, we address the question of whether or not FK 506 adversely affects the ability of myeloid progen-
itors in the bone marrow (BM) to regenerate and produce 
blood cells during the early phases of endogenous recovery 
after BM depletion or exogenous recovery after BM abla-
tion and BM transplantation (BMT). This is an important 
question for several reasons. First, FK 506 is being tested 
as a means to combat graft-versus-host disease (GVHD) in 
allogeneic BMT patients. Since it is known that T-cell 
depletion of the BM before transplantation increases the 
likelihood that the BM will fail to engraft I and. further-
more. that FK 506 decreases T-cell activity,2.3 including 
the production of certain cytokines,4-6 it is possible that 
the loss of T-cell activities could alter hematopoietic 
recovery or engraftment. 
Since survival after BMT depends on minimizing the 
period of neutropenia and thrombocytopenia caused by 
BM ablation, and since regeneration ofblood cells depends 
on previous regeneration of precursors and cellularity in 
the BM, we decided to survey the effects of FK 506 at 
selected times and doses on early regeneration after whole 
body irradiation (WBI) or WBI plus BMT. The mouse was 
used as a model system because there are a variety of 
well-characterized assays available for hematopoietic re-
covery in mice. RepopUlation of BM precursors, such as 
spleen colony forming cells, normally precedes and is 
necessary for the subsequent recovery of BM cellularity 
which, in tum, is responsible for recovery of blood cell 
counts. For endogenous recovery, the time of repopula-
tion depends on the radiation dose and, for exogenous 
recovery, it depends on the BM cell dose. Based on 
previous studies,1-16 times of recovery, radiation doses, 
and the BM cell dose used were selected to survey the 
potential of FK 506 to adversely affect hematopoietic 
recovery. 
MATERIALS AND METHODS 
The mice were female FI (C57BU6J x DBAI2J), purchased from 
Jackson Laboratories (Bar Harbor, Me) and used between 3 and 
8 months of age. Except where noted, there were 10 mice per 
group. All mice were given food and acidified (pH 2.4) water ad 
libitum. 
WBI was administered at 97 Rlmin using a Cesium 137'Y source 
(J.L Shepherd, Mark I Model 68, San Fernando, Calif), Groups 
of mice were given either 3 mglkg pure FK 506 (I1.1 mglkg of 
powder) or the equivalent amount of FK 506 diluent. Both were 
administered subcutaneously each day from the day of irradiation 
to the day of assay. An additional control group was not injected. 
FK 506 was provided by Fujisawa Pharmaceutical Co (Osaka. 
Japan). FK 506 with carrier solvent HCO-60 (chremophor EL) 
and D-mannitol was diluted in normal saline. The groups given 
"diluent" were given at an equivalent concentration of HCO-60 
and D-mannitol in the same volume (0.1 mUg mouse) in normal 
saline. 
Cell counts were performed with a Coulter Model ZBI elec-
tronic particle counter (Coulter Electronics. Marietta, Ga). Cell 
collection. cell injection, and analyses of endogenous spleen 
colony forming units (E-CFU-S) and exogenous CFU-S were 
performed as described previously.17 
Data values from the noninjected and diluent-injected control 
groups were averaged, and standard errors were calculated to 
reflect both within and between group variations. The two-way 
Student's t test was applied to detect significant effects of FK 506. 
Groups with P :s; .05 were considered significantly different. 
RESULTS AND DISCUSSION 
For endogenous repopulation studies, three groups of mice 
were given 550 R. The FK 506 or diluent was administered 
for 10 days. On day 9, hematocrit (HCT) and white blood 
cell counts (WBC) were done. At 10 days, the animals 
were killed and marrow cellularity and E-CFU-S deter-
mined. There was no significant effect of FK 506 on any of 
these parameters (Table 1). 
Exogenous BM recovery was measured 8 days after 
lethal irradiation and injection of 5 x 106 BM cells to each 
recipient: there were 5 mice per group. There was no 
significant effect of FK 506 on HCT, WBC, or BM 
cellularity (Table 2). Recovery of exogenous precursors in 
these primary BMT recipients was evaluated by pooling 
the BM cells from the entire group and transplanting that 
number of cells equivalent to 1/15 of the humeral cell count 
Table 1. Endogenous Recovery After Sublethal Whole Body 
Irradiation (550 R) 
Blood 
Bone Marrow. 
wee CeUslHumerus SpIea1. 
Treatment Group HCT (x HflmL) (MUlions) e.{;FU-S 
FK 506 (n = 10) 43:!: 0.3 17:!: 1.5 81:0.5 6:!: 1.0 
Control (n = 20) 32 :t 0.4 17:t 1.5 7 :t 0.4 5:t 1.1 
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Table 2. Exogenous Recovery 8 Days After Transplantation of 5 
x 10- Bone Marrow Cells Into LethIIlly Irradiated Mice (950 R) 
Blood 
Bone Marrow. 
wee CellslHumerus 
Treatment Group HCT (xlOSImL) (MIIIons) 
FK506 (n = 5) 45:!: 0.6 50:!: 11.2 7:!: 0.5 
Control (n = 10) 46:!: 0.5 88 :!: 16.0 8 :!:0.5 
into irradiated recipients. The 1/15 humerus value was 
chosen from previous data and, in preliminary experi-
ments with small numbers of mice, gives countable num-
bers of CFU-S12• 14-16 There were 10 secondary recipients 
and lO additional control mice given only the irradiation in 
each group (Table 3). After 12 days, HCT, WBC, and 
CFU-S I2 were assayed in the secondary recipients (Table 
3). There was no affect of prior FK 506 treatment on these 
parameters as assayed in secondary recipients. Since 1/15 
of a humerus produced 15 ::!: 0.9 spleen colonies and a 
seeding fraction for CFU-S I2 of about 10%.18 the spleen 
colony forming cells at this time point can be estimated to 
be 2225 per humerus in the FK 506-treated group. This is 
on the rising portion of the recovery curve for these cells. 
Table 3. Hematopoietic Repopulation of Secondary Recipients 
of 1/15 Humerus Harvested 8 Days After Transplantation of 5 x 
10- Bone Marrow Cells Into PrImary Irradiated Recipients 
Blood 
Donor wee Spleen. 
Group HCT (xlOS/mL) CFU-S'2 
FK506 35:!: 0.5 9:!: 0.8 15:!: 0.9 
Control 34:!: 1.0 18:!: 7.5 18:!: 2.0 
No donor 3O:!:0.6 3 :!:0.4 3:!: 1.0 
There were 10 recipients 01 cells from FK 506-treated donors. 20 recipients of 
cells from control groups. and 10 mice given 950 R only and no donor cells. 
3237 
. 
and any differences in iecovery should have been detect-
able. 
Thus. on the basis of these investigations. there were no 
detected hematopoietic effects of FK 506 in mice when 
administered for 8 to lO days during the early phase of 
recovery from sublethal irradiation or lethal irradiation 
followed by BMT. Longer exposure times, higher doses, 
or different routes of administration of FK 506 in an animal 
model may reveal effects not observed in the present 
study. 
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